Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
984 articles about Boehringer Ingelheim Fremont, Inc.
-
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus
4/27/2023
BioMed X announced the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs.
-
RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence
4/21/2023
RetinAI Medical AG, a leader in clinical and imaging data management software and advanced analytics using artificial intelligence for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim.
-
Cognizant and Boehringer Ingelheim Collaborate on Unified Cloud Platform to Speed the Delivery of Life Saving Therapies
4/11/2023
Cognizant announced it is working with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development.
-
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
3/29/2023
Boehringer Ingelheim reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.
-
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
1/9/2023
Boehringer Ingelheim and 3T Biosciences, announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs.
-
Eli Lilly’s and Boehringer’s Jardiance met its primary outcome in the Phase III EMPA-KIDNEY study, the largest and broadest SGLT2 inhibitor trial in chronic kidney disease. -
Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials
10/27/2022
Medidata, a Dassault Systèmes company, and Boehringer Ingelheim announced a five-year renewal of their collaboration in the wider area of electronic data capture.
-
University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs
10/20/2022
University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.
-
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
10/6/2022
Surrozen, Inc. (Nasdaq: SRZN) announced today that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for the treatment of retinal diseases.
-
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
9/5/2022
Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease.
-
Veterinary Students Conclude Summer Research Experience With Capstone Presentations at 2022 National Veterinary Scholars Symposium - Boehringer Ingelheim
8/8/2022
This weekend, nearly 600 veterinary students representing three dozen veterinary schools from across the US, Canada, France, Germany and the Netherlands marked the conclusion of a special summer research experience with a presentation of their findings at the National Veterinary Scholars Symposium.
-
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
8/3/2022
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
-
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
7/6/2022
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
7/6/2022
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
6/28/2022
BiomX Inc. announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease.
-
Boehringer and BiomX intend to use the discovery platform to identify biomarkers for a pathogenic bacterium thought to be associated with IBD. -
FDA Grants Boehringer Ingelheim Animal Health Conditional Approval for VETMEDIN®-CA1 (pimobendan) to Treat Canine Valvular Disease for Stage B2
6/21/2022
Boehringer Ingelheim Animal Health announced that the U.S. Food and Drug Administration Center for Veterinary Medicine has granted conditional approval of VETMEDIN®-CA1, which is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease, a form of chronic valvular heart disease in dogs.
-
The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes. -
Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
6/5/2022
Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty real-world study show that Jardiance® was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care.
-
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.